Volumetric growth rate of incidentally found meningiomas on immunotherapy

• Published in: Journal of neuro-oncology Vol. 166; no. 2; pp. 303 - 307
• Main Authors: Berger, Assaf, Mullen, Reed, Bernstein, Kenneth, Mashiach, Elad, Meng, Ying, Silverman, Joshua S., Sulman, Erik P., Golfinos, John G., Kondziolka, Douglas
• Format: Journal Article
• Language: English
• Published: New York Springer US 2024; Springer Nature B.V
• Subjects: Carcinoma, Non-Small-Cell Lung; Chemotherapy; Humans; Immunotherapy; Ipilimumab; Lung Neoplasms; Medicine; Medicine & Public Health; Melanoma; Meningeal Neoplasms - diagnostic imaging; Meningeal Neoplasms - pathology; Meningeal Neoplasms - therapy; Meningioma; Meningioma - diagnostic imaging; Meningioma - pathology; Meningioma - therapy; Metastases; Neurology; Nivolumab - therapeutic use; Non-small cell lung carcinoma; Oncology; Patients; PD-L1 protein; Pembrolizumab; Prospective Studies; Retrospective Studies; Tumors; Check-point inhibitors; Volumetrics; Immunotherapy; Meningioma
• ISSN: 0167-594X; 1573-7373
• DOI: 10.1007/s11060-023-04558-2

Purpose The expression of PD-L1 in high-grade meningiomas made it a potential target for immunotherapy research in refractory cases. Several prospective studies in this field are still on going. We sought to retrospectively investigate the effects of check-point inhibitors (CI) on meningiomas that had been naïve to either surgical or radiation approaches by following incidental meningiomas found during treatment with CI for various primary metastatic cancers. Methods We used the NYU Perlmutter Cancer Center Data Hub to find patients treated by CI for various cancers, who also had serial computerized-tomography (CT) or magnetic-resonance imaging (MRI) reports of intracranial meningiomas. Meningioma volumetric measurements were compared between the beginning and end of the CI treatment period. Patients treated with chemotherapy during this period were excluded. Results Twenty-five patients were included in our study, of which 14 (56%) were on CI for melanoma, 5 (20%) for non-small-cell lung cancer and others. CI therapies included nivolumab (n = 15, 60%), ipilimumab (n = 11, 44%) and pembrolizumab (n = 9, %36), while 9 (36%) were on ipilimumab/nivolumab combination. We did not find any significant difference between tumor volumes before and after treatment with CI (1.31 ± 0.46 vs. 1.34 ± 0.46, p=0.8, respectively). Among patients beyond 1 year of follow-up (n = 13), annual growth was 0.011 ± 0.011 cm 3 /year. Five patients showed minor volume reduction of 0.12 ± 0.10 cm 3 (21 ± 6% from baseline). We did not find significant predictors of tumor volume reduction. Conclusion Check-point inhibitors may impact the natural history of meningiomas. Additional research is needed to define potential clinical indications and treatment goals.